AsclepiX Therapeutics

AsclepiX Therapeutics: Private, ophthalmology focused early stage company; technology out of Johns Hopkins. Lead compound AXT107: novel peptide, inhibiting VEGF and activating Tie2 is the only therapeutic in clinical development for DME and wet AMD that was identified through a process of Artificial Intelligence, mining the human proteome for cryptic anti angiogenic and homeostatic peptides, rather than through a standard drug development process. $35M Series A (June 2020) led by Perceptive Xontogeny Venture Fund, Rapha Capital and Barer & Son Capital
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Pre-Clinical Stage
Disease Space
Oncology, Ophthalmology
Listing
Private
Website:
Profiles:
Address:
301 West 29th Street
Suite 2004
Baltimore, MD 21211
United States

Upcoming Company Event Participation